All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Roche Venture Fund
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 28, 2021
Details:
The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $33.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2020
Details:
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
